Recurrent Thromboembolism in Cancer Patients: Incidence and Risk Factors

ABSTRACT

In contrast with the paucity of data on the risk of a first episode of thrombosis in cancer patients, the frequency of recurrent thromboembolism in patients with malignancy has been extensively investigated, both during anticoagulation and after its cessation. Cancer patients are more likely to develop recurrent thromboembolism and major bleeding during anticoagulation than patients without malignancies. These events are more pronounced during the first weeks of treatment and increase with cancer severity. Since they are not associated with anticoagulant intensities outside the therapeutic range, possibilities for improvement using the current paradigms of anticoagulation seem limited and new treatment strategies should be developed. In this regard, the use of low-molecular-weight heparins for initial treatment and long-term anticoagulation in cancer patients with venous thrombosis seems promising. Furthermore, patients with active cancers exhibit a particularly high risk of recurrent venous thromboembolism after the cessation of anticoagulation. In view of the persisting high risk for recurrent thrombotic events in cancer patients, and the acceptable risk of bleeding, prolonged warfarin treatment should be considered in such patients for as long as the cancer is active.

KEYWORDS

Thromboembolism - anticoagulation - cancer - risk

REFERENCES

• 1 Sproul E E. Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis.  Am J Cancer . 1938;  34 566-585
• 2 Cogo A, Bernardi E, Prandoni P. et al . Acquired risk factors for deep-vein thrombosis in symptomatic outpatients.  Arch Intern Med . 1994;  154 164-168
• 3 Samama M M, for the Sirius Study Group. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients.  Arch Intern Med . 2000;  160 3415-3420
• 4 Prandoni P, Piccioli A, Girolami A. Cancer and venous thromboembolism: an overview.  Haematologica . 1999;  84 437-445
• 5 Otten H M, Prins M H. Venous thromboembolism and occult malignancy.  Thromb Res . 2001;  102 187-194
• 6 Piccioli A, Prandoni P. Venous thromboembolism as first manifestation of cancer.  Acta Haematol . 2001;  106 13-17
• 7 Shen V S, Pollak E W. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified?.  South Med J . 1980;  73 841-843
• 8 Huber O, Bounameaux H, Borst F, Rohner A. Postoperative pulmonary embolism after hospital discharge. An underestimated risk.  Arch Surg . 1992;  127 310-313
• 9 Levine M N. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy.  Thromb Haemost . 1997;  78 133-136
• 10 Pritchard K I, Paterson A HG, Paul N A, Zee B, Fine S, Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer.  J Clin Oncol . 1996;  14 2731-2737
• 11 Monreal M, Davant E. Thrombotic complications of central venous catheters in cancer patients.  Acta Haematol . 2001;  106 69-72
• 12 Hutten B, Prins M, Gent M, Ginsberg J, Tijsen J GP, Büller H R. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.  J Clin Oncol . 2000;  18 3078-3083
• 13 Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators.  N Engl J Med . 1997;  337 657-662
• 14 Palareti G, Legnani C, Agnes L. et al . A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy.  Thromb Haemost . 2000;  84 805-810
• 15 Prandoni P, Lensing A WA, Piccioli A. et al . Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.  Blood . 2002;  100 3484-3488
• 16 Meyer G, Marjanovic Z, Valcke J. et al . Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer.  Arch Intern Med . 2002;  162 1729-1735
• 17 Lee A Y, Levine H N, Bakar R I. et al . Low molecular weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer.  N Engl J Med . 2003;  349 146-153
• 18 Prandoni P, Lensing A WA, Cogo A. et al . The long-term clinical course of acute deep venous thrombosis.  Ann Intern Med . 1996;  125 1-7
• 19 Hansson P O, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis. Incidence and risk factors.  Arch Intern Med . 2000;  1260 769-774
• 20 Heit J A, Mohr D N, Silverstein M D, Petterson T M, O'Fallon W M, Melton III J L. Predictors of recurrence after deep vein thrombosis and pulmonary embolism. A population-based cohort study.  Arch Intern Med . 2000;  160 761-768